{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:42:31Z","timestamp":1788349351436,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T00:00:00Z","timestamp":1208390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Although D\u2212 patients should receive red blood cells (RBCs) from D\u2212 donors, the scarcity of D\u2212 blood components in certain situations makes the transfusion of D+ RBCs unavoidable. Therefore it is recommended that guidelines be developed in order to standardize transfusion policy in these scenarios.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> We have prospectively evaluated a policy for the use of D+ RBCs in 905 D\u2212 patients. The amount of D\u2212 RBCs saved as well as the incidence of hemolytic reactions and anti\u2010D alloimmunization were assessed.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> 554 patients received D\u2212 RBCs while 351 received a total of 1032 D+ RBCs, all of them within our criteria for the acceptable use of D+ RBCs. This strategy allowed us to save 25.6\u2003percent of D\u2212 RBCs (1032 out of 4024 RBCs requested). No hemolytic reactions were reported. The incidence of alloimmunization was 21.4\u2003percent. Most patients who developed anti\u2010D did so within the first 2 or 4 RBCs transfused (64% after the first 2 RBCs transfused and 88% after the first 4). In multivariate analysis the age of less than 77\u2003years was the only predictor for alloimmuization (HR\u2003=\u20032.48 [95% CI\u2003=\u20031.21\u20103.81]; p\u2003=\u20030.014).<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> The use of D+ RBCs in selected D\u2212 patients does not induce adverse reactions and allows the saving of a significant number of D\u2212 RBCs.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2008.01700.x","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T15:10:11Z","timestamp":1208445011000},"page":"1318-1324","source":"Crossref","is-referenced-by-count":85,"title":["Prospective evaluation of a transfusion policy of D+ red blood cells into D\u2212 patients"],"prefix":"10.1111","volume":"48","author":[{"given":"Jose R.","family":"Gonzalez\u2010Porras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio F.","family":"Graciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Perez\u2010Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Martin\u2010Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.1971.tb04425.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1971.tb02731.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1974.tb50783.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(76)90365-3"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1981.21181127486.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198906000-00015"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1994.34794330009.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.351196110898.x"},{"key":"e_1_2_6_10_2","first-page":"22","article-title":"Transfusion of RhD\u2010incompatible blood components in RhD\u2010negative blood marrow transplant recipients","volume":"6","author":"Asfour M","year":"2004","journal-title":"Med Gen Med"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39070763.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28488265260.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood.V58.1.122.122","article-title":"Suppression of transfusion\u2010related alloimmunization in intensively treated cancer patients","volume":"58","author":"Holohan TV","year":"1981","journal-title":"Blood"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00289.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00394.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01446.x"},{"key":"e_1_2_6_17_2","volume-title":"Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten","author":"Federal Medical Association of Germany.","year":"2003"},{"key":"e_1_2_6_18_2","volume-title":"Guidelines for the blood transfusion services in the UK","author":"National Blood Service.","year":"2005"},{"key":"e_1_2_6_19_2","volume-title":"Technical manual of the American Association of Blood Banks","author":"Brecher ME","year":"2002"},{"key":"e_1_2_6_20_2","unstructured":"Guidelines for the use of group O D negative red cells including contingency planning for large scale emergencies. National Blood Services in England 2003. Available from: URL:http:\/\/www.blood.co.uk\/hospitals\/library\/pdf\/oneg.pdf"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.007"},{"key":"e_1_2_6_22_2","first-page":"34","article-title":"Immune immunity and ageing in man: annual review 2006\/2007","volume":"43","author":"Pawelec G","year":"2008","journal-title":"Exp Gerontol"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2008.01700.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2008.01700.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:21:46Z","timestamp":1697260906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2008.01700.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1537-2995.2008.01700.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2008.01700.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}